Identifying patients with late-stage, non-small cell lung cancers who may benefit from treatment with the drug Xalkori.
This test is always reflexed when EGFR is initially ordered.
1. A pathology report is required in order for testing to be performed. Acceptable pathology reports include working drafts, preliminary pathology or surgical pathology reports.
2. A reason for testing must be provided. If this information is not provided, an appropriate indication for testing may be entered by Mayo Clinic Laboratories.
This test is intended to be used for therapeutic purposes in pulmonary carcinoma. This FISH assay does not rule out other chromosome abnormalities.
While results may indicate the likely response to ALK inhibitor therapy, selection of treatment remains a clinical decision.
Mayo Clinic Laboratories